Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02180711 · ClinicalTrials.gov registry record · Phase 1
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
A Phase 1 study of Non-Hodgkin Lymphoma, sponsored by Acerta Pharma.
- Active
- Registry status
- Phase 1
- Development phase
- 113
- Enrollment target
- 20
- Study locations
NCT02180711: Active Phase 1 study of Non-Hodgkin Lymphoma, sponsored by Acerta Pharma.
NCT02180711 is a Phase 1 study of Non-Hodgkin Lymphoma that is active but no longer recruiting, run by Acerta Pharma. The registered enrollment target is 113 participants, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (32% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02180711, a Phase 1 study of Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Acerta Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 113 participants
- Enrollment target
- 20
- Study locations
Study Summary
Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR. Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL
Primary Outcome
Treatment-emergent adverse events were used to characterize the safety profile of acalabrutinib alone or in combination with rituximab in participants with relapsed/refractory follicular lymphoma (R/R FL).
Conditions Studied
Interventions
- DRUG Lenalidomide
- DRUG acalabrutinib
- DRUG rituximab (IV)
Study Locations (20)
California
- Research Site - Downey
- Research Site - Duarte
- Research Site - Fountain Valley
- Research Site - Santa Monica
New York
- Research Site - Hawthorne
- Research Site - Lake Success
- Research Site - New York
- Research Site - Syracuse
Illinois
- Research Site - Chicago
- Research Site - Chicago
- Research Site - Chicago
Arizona
- Research Site - Tucson
Florida
- Research Site - Coral Gables FL
Kentucky
- Research Site - Louisville
Louisiana
- Research Site - New Orleans
Michigan
- Research Site - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2014-12-29 |
| Est. Completion | 2028-12-29 |
| Phase | Phase 1 |
What the registry record for NCT02180711 still lists
NCT02180711 is an interventional study that assigns participants to a tested intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (32% lower).
The record links to 1 condition, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Lenalidomide is the first listed.
NCT02180711 names 20 study sites across 12 states, led by California, New York, Illinois.
Frequently Asked Questions
What is clinical trial NCT02180711 about?
NCT02180711 is a clinical study titled "Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma". Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR. Part 3: To characterize the safety ...
What is the current status of trial NCT02180711?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 113 participants. The study started on 2014-12-29. Estimated completion is 2028-12-29.
What conditions does trial NCT02180711 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT02180711?
The interventions under investigation include: Lenalidomide (DRUG), acalabrutinib (DRUG), rituximab (IV) (DRUG).
Who is sponsoring clinical trial NCT02180711?
This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02180711 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02180711's enrollment target sits among peer trials
113 33rd of 106 higher than 74 of 106 other Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00748254 · 113 participants
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
- NCT04753190 · 113 participants · NA
Light Timing Study
- NCT05799248 · 113 participants · Phase 3
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
- NCT07216105 · 113 participants · Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI